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N E U R O S C I E N C E
Intracellular delivery of Parkin rescues neurons 
from accumulation of damaged mitochondria 
and pathological -synuclein
Eunna Chung1*, Youngsil Choi1*, Jiae Park1, Wonheum Nah1, Jaehyung Park1, Yukdong Jung1, 
Joonno Lee1, Hyunji Lee1, Soyoung Park1, Sunyoung Hwang1, Seongcheol Kim1, Jongseok Lee1, 
Dongjae Min1, Junghwan Jo1, Shinyoung Kang1, Minyong Jung1, Phil Hyu Lee2,  
H. Earl Ruley3, Daewoong Jo1†
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by mitochondrial dysfunction, 
Lewy body formation, and loss of dopaminergic neurons. Parkin, an E3 ubiquitin ligase, is thought to inhibit 
PD progression by removing damaged mitochondria and suppressing the accumulation of -synuclein and other 
protein aggregates. The present study describes a protein-based therapy for PD enabled by the development 
of a cell-permeable Parkin protein (iCP-Parkin) with enhanced solubility and optimized intracellular delivery. 
iCP-Parkin recovered damaged mitochondria by promoting mitophagy and mitochondrial biogenesis and suppressed 
toxic accumulations of -synuclein in cells and animals. Last, iCP-Parkin prevented and reversed declines in tyrosine 
hydroxylase and dopamine expression concomitant with improved motor function induced by mitochondrial 
poisons or enforced -synuclein expression. These results point to common, therapeutically tractable features in 
PD pathophysiology, and suggest that motor deficits in PD may be reversed, thus providing opportunities for 
therapeutic intervention after the onset of motor symptoms.
INTRODUCTION
Parkinson’s disease (PD) and Parkinson-like diseases belong to a 
family of neurodegenerative disorders characterized by the loss of 
dopaminergic neurons, leading to clinical symptoms such as exercise 
relaxation, tremor, and postural instability (1). The diseases present 
in a variety of ways, which has confounded efforts to understand the 
underlying pathophysiology. Sporadic PD has been linked to the 
spread of -synuclein–containing Lewy bodies (and associated 
neurodegeneration) that spread from the olfactory bulb and the 
medulla oblongata in the central nervous system (2) to the pontine 
tegmentum, the midbrain, and the amygdala, at which point, the 
pathognomonic motor symptoms of PD appear. Aggregated or 
overexpressed -synuclein induces similar pathology in experimental 
animals (3). Familial early-onset PD is linked to genetic mutations 
in proteins such as Parkin and phosphatase and tensin homolog 
(PTEN)–induced kinase 1 (PINK1) that regulate mitophagy, a 
process to remove damaged mitochondria, which protect against 
PD (4, 5). However, Lewy bodies are not observed in familial PD 
or in knockout (KO) mice bearing analogous mutations. Likewise, 
Lewy bodies are not observed in parkinsonian conditions induced 
in animals and humans by mitochondrial poisons such as 1-methyl- 
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and rotenone. These 
differences have raised questions about the relevance of different 
animal models to sporadic PD and the development of mechanism-based 
therapies to treat the disease. Moreover, there is widespread concern 
that by the time motor symptoms appear, which is when the disease 
is normally diagnosed, the pathology has become irreversible (6).
Parkin functions as an E3 ubiquitin ligase and acts downstream 
of PINK1 and protein deglycase (DJ-1) in the damage-induced 
mitophagy response (4, 5, 7). Enforced Parkin gene expression has 
been shown to suppress PD phenotypes in a variety of cell and animal 
models following acute intoxication with mitochondrial poisons or 
exposure to aggregated -synuclein (8–10). These findings suggest 
that Parkin could provide an effective PD therapy, assuming (i) 
practical methods can be developed to deliver Parkin to affected 
areas of the brain, and (ii) the damage to dopaminergic neurons can 
be arrested (or reversed) by this treatment after the onset of motor 
symptoms (3, 5, 7, 11).
The present study addressed both of these goals. First, we describe 
the development of an efficient therapeuticmolecule systemic 
delivery technology (TSDT) to deliver proteins into mammalian cells 
and tissues. Specifically, sequence-optimized advanced macromolecule 
transduction domains (aMTDs) were developed to facilitate efficient 
bidirectional transport of proteins across the plasma membrane 
and allow systemic protein delivery to a variety of tissues, including 
the brain. Second, we developed an improved cell-permeable Parkin 
(iCP-Parkin) by attaching an aMTD sequence and a solubilization 
domain (SD) to the full-length human Parkin protein. Purified 
recombinant iCP-Parkin protein displayed a high level of cell 
permeability that was aMTD dependent and maintained the E3 
ubiquitin ligase activity of native Parkin. Most importantly, iCP- Parkin 
(but not control proteins without the aMTD sequence) suppressed 
neuronal toxicity in cultured cells and animals exposed to mitochondrial 
poisons and aggregated -synuclein. The response included a restoration 
of tyrosine hydroxylase (TH)–positive dopaminergic neuronal cells in the 
striatum and the midbrain, concomitant with enhanced dopamine 
(DA) expression and restoration of gross motor function. These 
results suggest common therapeutically tractable features in the 
pathophysiology of PD and Parkinson-like diseases and show that 
the motor deficits in PD may not be as irreversible as often assumed.
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RESULTS
Enhanced protein delivery with sequence-optimized aMTDs
While a variety of hydrophobic sequences have been empirically 
found to enhance the delivery of protein cargos into cells and tissues 
(12, 13), we identified six critical factors: amino acid length, bending 
potential (proline presence and location), rigidity/flexibility (instability 
index), aliphatic index, hydropathy [grand average of hydropathy 
(GRAVY)], and the location of hydrophobic and aliphatic residues 
that contributed to optimal protein delivery (table S1). After excluding 
sequences with outlying values for bending potential, rigidity, and 
hydrophobicity, we determined the average values and ranges for 
each of the six critical factors and synthesized 136 synthetic peptides 
(designated aMTDs) that covered a range of values for each critical 
factor (table S1). These included otherwise consensus-conforming 
peptides from which at least one of the critical factors was omitted 
[unsatisfying peptides (uPs)]. Each peptide was tested for its ability 
to deliver a fluorescein isothiocyanate (FITC)–labeled reporter 
protein into RAW264.7 cells. Protein uptake was measured by 
flow cytometry and confocal laser scanning microscopy. The uPs 
engineered beyond certain conditions of denoted critical factors or with 
varied bending potentials depending on proline were largely unable to 
enhance protein delivery (fig. S1, A and C). As illustrated in fig. S1B, 
aMTDs that satisfied all critical factors (aMTD910) demonstrated 
up to 13-fold greater cell permeability than previous hydrophobic 
transduction peptides such as membrane translocating motif (MTM) 
and macromolecule transduction domain 85 (MTD85).
Development of a cell-permeable Parkin with  
enhanced solubility
An earlier study described a cell-permeable Parkin able to protect 
mice from chemically induced PD. However, the protein suffered 
from low solubility and was therefore unsuited for clinical development. 
To develop a cell-permeable Parkin with enhanced therapeutic 
potential, the protein was modified in three steps. First, we added a 
99–amino acid protein solubilization domain B (SDB), derived from 
cytochrome b of Rattus norvegicus. This domain had been pre-
viously shown to enhance the solubility of recombinant proteins (14). 
Second, aMTD524-Parkin-SDB (Fig. 1A) was selected for the 
current study with the desired combination of solubility and cell 
delivery. Together, these steps illustrate practical application of the 
TSDT platform.
Mechanism of aMTD-mediated protein delivery
As assessed by flow cytometry and fluorescence/confocal microscopy, 
iCP-Parkin was highly cell permeable in a dose- and time-dependent 
manner, whereas the same protein without an aMTD or dye only was 
not, suggesting that the aMTD sequence is essential for intracellular 
and systemic delivery (Fig. 1, B and C, and fig. S2, A to C and E). 
aMTD-dependent iCP-Parkin delivery was observed in all cell types 
examined including primary mouse neurons (Fig. 1C) as well as human 
neuronal (SH-SY5Y) and astrocyte (NHA) cells (Fig. 1B and fig. 
S2C). Uptake was decreased by EDTA treatment (Fig. 1D) and 
low temperature (Fig. 1E) but was unaffected by depleting cells of 
adenosine 5′-triphosphate (ATP; Fig. 1F) or surface proteins (Fig. 1G), 
or by inhibitors of microtubule cytoskeleton (Fig. 1H), clathrin- 
dependent endocytosis (Fig. 1I), macropinocytosis (Fig. 1J), or lipid 
raft–dependent uptake (Fig. 1K). In short, aMTD-mediated protein 
delivery appeared to involve direct penetration of an intact lipid 
bilayer by an energy-independent mechanism.
We reasoned that if aMTD-containing cargos penetrate the plasma 
membrane directly, then the proteins should be capable of bidirectional 
movement in and out of cells. To test this possibility, C2C12 cells 
were pretreated with FITC-labeled iCP-Parkin washed to remove 
noninternalized protein and mixed with RAW264.7 cells bound to 
a phycoerythrin (PE)–labeled anti-CD14 antibody. The appearance 
of flow-sorted double-positive FITC/PE suggests that iCP-Parkin 
exited C2C12 cells and entered neighboring RAW264.7 cells (Fig. 1L). 
Next, we questioned whether cell-to-cell transfer involved biologically 
active protein, which proved to be the case as cells preloaded with 
iCP-Parkin exerted a protective effect on neighboring neurotoxin- 
treated cells (Fig. 1M).
iCP-Parkin is intracellularly delivered to deep brain tissues
To examine systemic protein delivery, iCP-Parkin and non–CP- 
Parkin (a control Parkin protein without the aMTD sequence) were 
labeled with FITC, administered intravenously, and the fluorescent 
signal was monitored in major organs including the brain, liver, 
heart, kidney, lung, and spleen. Florescent signal was observed in all 
tissues examined but only in mice injected with FITC-labeled 
iCP-Parkin (fig. S2E). We next evaluated the distribution of Cy5- 
labeled iCP-Parkin after intravenous injection to nude mice using 
an in vivo imaging system (IVIS). In fig. S2D, strong fluorescence of 
Cy5-labeled iCP-Parkin was detected in the entire body including 
the brain region at 3 hours after injection compared with mice that 
received Cy5 only. The fluorescence intensity gradually weakened 
over time. In fig. S2D, excised brains from Cy5-labeled iCP-Parkin–
treated mice showed stronger Cy5 fluorescence signals than controls.
iCP-Parkin was detected in both the substantia nigra and striatum 
as assessed by Western blot (Fig. 2A; analyzed also in the whole-
brain sample) and enzyme-linked immunosorbent assay (ELISA) 
analysis (Fig. 2B). Maximum levels of iCP-Parkin (56.4 ng/g is 
present at 2 hours in striatum) were observed 2 hours after injection 
(Fig. 2, A and B), and the protein was colocalized with markers for 
neurons (Fig. 2C), astrocytes (fig. S2F), and microglia (fig. S2G), 
including TH-positive (dopaminergic) neurons of the substantia 
nigra (fig. S2H).
The kinetics of iCP-Parkin delivery to the brain was also assessed 
by using liquid chromatography–tandem mass spectrometry (LC-
MS/MS) to detect a unique peptide (AVALIVVPALAPMIVFVR) 
from the iCP-Parkin N terminus (Fig. 2, D and E). The maximum 
amount of iCP-Parkin was detected at the 30-min time point in 
the whole-brain samples of the normal mouse model (Fig. 2E) and 
showed gradually decreased levels over time (up to 24 hours). 
Together, these data suggest that iCP-Parkin crosses the blood-brain 
barrier (BBB) and is intracellularly delivered to deep brain tissues.
iCP-Parkin autoubiquitination and cytoprotective activities 
do not require PINK1
Since PINK1 activates Parkin by phosphorylation-induced confor-
mational changes, we considered the possibility that iCP-Parkin 
might be in a constitutively active conformation, for example, due 
to refolding during purification or removal of N-terminal sequences 
(15). Although iCP-Parkin could serve as a substrate for PINK1 as 
determined by Western blot analysis probing with an anti–pSer65- 
Parkin antibody (fig. S3A), the unphosphorylated protein was 
active as an E3 ubiquitin ligase (fig. S3B). Ser65 phosphorylation was 
enhanced in cells overexpressing PINK1 and further increased by 
treatment with carbonyl cyanide m-chlorophenyl hydrazone (CCCP), 
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a mitochondrial uncoupling agent (fig. S3C). Low levels of basal 
and CCCP-induced pSer65 reactivity observed in PINK1 KO cells 
(fig. S3D) presumably involve kinases other than PINK1. Last, 
PINK1 wild-type (WT) and KO cells were similarly sensitive to 
CCCP treatment and to iCP-Parkin cytoprotection (fig. S3E), 
further suggesting that iCP-Parkin function is uncoupled from 
PINK1 regulation.
iCP-Parkin induces mitophagy and mitochondrial biogenesis
In principle, therapeutic proteins provide a way to regulate biochemical 
functions in cells and tissues under non–steady-state conditions 
and directly influence biochemical pathways responsible for disease 
pathophysiology. A series of experiments were performed to determine 
the extent to which iCP-Parkin functions like native Parkin (Fig. 3A), 
which acts downstream of PINK1 and DJ-1 in the damage-induced 
Fig. 1. Purification and characterization of iCP-Parkin; aMTD/SD-fused Parkin recombinant protein is cell permeable via direct cell-to-cell transfer. (A) Structure 
of Parkin recombinant proteins fused to aMTD524 and SDB (iCP-Parkin). SDS-PAGE (reducing and nonreducing) image of iCP-Parkin. (B) Neuronal (SH-SY5Y cell) measured 
by flow cytometry and confocal laser scanning microscopy, demonstrating the intracellular localization of iCP-Parkin. (C) Immunofluorescence staining data (green 
fluorescence) showing intracellular location of iCP-Parkin in primary neurons when cotreated with or without 6-OHDA at 2 and 24 hours. -III-Tubulin was also costained 
and detected as red fluorescent signal. The representative data are presented, and the tests were carried out in quadruplicate (n = 4). aMTD-mediated delivery of iCP- 
Parkin is notably affected by EDTA treatment (D) and low temperature (E) but unaffected by pretreatment of cells with the ATP-depleting agent antimycin (F), proteinase K (G), the 
microtubule inhibitor Taxol (H), a clathrin-mediated endocytosis blocker, chlorpromazine (I), a macropinocytosis blocker, amiloride (J), or a lipid raft–mediated endo-
cytosis blocker, methyl--cyclodextrin (K). (L) Cell-to-cell transfer of iCP-Parkin. C2C12 cells (donor cells) were pretreated with FITC–iCP-Parkin (green) for 2 hours and were 
mixed with RAW264.7 cells (recipient cells) labeled with PE-CD14 antibody (red) for 2 hours. Green/red fluorescent double-positive cells were analyzed by flow cytom-
etry. (M) The cytoprotective effect of iCP-Parkin via cell-to-cell transfer. iCP-Parkin–treated SH-SY5Y cells (for 2 hours) incubated with GFP-transfected SH-SY5Y cells for 
6 hours. These mixed cells were treated with 2 mM MPP+ for 24 hours. Apoptosis of GFP-positive cells was analyzed by an annexin V/7-AAD apoptosis detection assay. 
Quantification of cytoprotective effect by cell-to-cell transferred iCP-Parkin. Data are represented as the means ± SD with Student’s t test.
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mitophagy pathway (4, 5, 7) and plays a broadly protective role in 
maintaining neuronal cell function and viability (16–19).
First, iCP-Parkin physically interacted with endogenous PINK1 in 
response to toxin treatment (Fig. 3B) and colocalized with PINK1 
on mitochondria (fig. S4A). In contrast, in the absence of toxin 
treatment, the cells appeared to accumulate less iCP-Parkin (fig. S4N), 
and the protein remained evenly distributed in the cytoplasm 
(fig. S4A). In addition, iCP-Parkin accumulates 2.1- and 2.9-fold in 
damaged mitochondria of Parkin WT and KO cells, respectively (Fig. 3, 
C and D). iCP-Parkin increased the ubiquitination of mitochondrial 
Rho guanosine triphosphatase (GTPase) 2 (Miro2) and other various 
mitochondrial Parkin substrates (Fig. 3E and fig. S4, B and C) 
and promoted mitophagy as assessed by biomarker expression 
(Fig. 3, F and G). Compared with the vehicle group, mitophagy 
staining was increased by two- and four-fold in the CCCP only and 
iCP-Parkin–cotreated group, respectively (Fig. 3G). However, an 
enzymatically inactive iCP-Parkin mutant [C444S (point-mutated 
variant from a catalytic cysteine at position 444 to serine) equivalent 
to the catalytically inactive C431S mutant of native Parkin] failed to 
ubiquitinate the Parkin substrate (fig. S4, D and E) and did not 
stimulate mitophagy in CCCP-treated cells (fig. S4F).
Cytoprotection by iCP-Parkin was associated with enhanced levels 
of mitochondrial proteins, including cytochrome c oxidase I (COX1), 
succinate dehydrogenase complex flavoprotein subunit A (SDH-A; 
Fig. 3H), translocase of the outer membrane mitochondrial import 
receptor subunit 20 (Tom20), translocase of the inner membrane 23 
(Tim23), mitofusin 1 and 2 (MFN1 and MFN2), compared with the re-
duced levels seen in CCCP-treated cells (fig. S4H), and the effect re-
quired an aMTD domain (fig. S4G). iCP-Parkin also increased the 
ubiquitination of Parkin-interacting substrate (PARIS) and the expression 
of genes involved in mitochondrial biogenesis: peroxisome proliferator–
activated receptor gamma coactivator 1 (PGC-1), transcription 
factor A, mitochondrial (TFAM), and nuclear respiratory factor 1 and 2 
(NRF1 and NRF2; Fig. 3I and fig. S4I). These results suggest that 
iCP-Parkin promotes mitochondrial biogenesis in toxin-treated cells.
On a cellular level, CCCP and 1-methyl-4-phenylpyridinium 
(MPP) induced dose-dependent increases in reactive oxygen species 
(ROS), reduced ATP levels, and increased apoptosis that were 
recovered by iCP-Parkin (Fig. 3, J to L, and fig. S4, J and K) in a 
dose-dependent manner (fig. S4L) and were accompanied by the 
expected changes in proapoptotic (p53, cytochrome C, and cleaved 
caspase-3) and antiapoptotic (Bcl2) biomarkers (fig. S4M).
Fig. 2. iCP-Parkin is delivered to the brain through the BBB. (A and B) Time course analysis of brain tissue permeability. The level of each protein in the brain tissue was 
measured by Western blot (A) and ELISA (B) (n = 3). All analysis samples were collected after intravenous injection of iCP-Parkin (100 mg/kg). The molecular weights of iCP-Parkin 
and endogenous Parkin are 63 and 53 kDa, respectively. Western blot analysis of substantia nigra and striatum tissues was carried out in triplicate. *P < 0.001 versus 0 hour (B). 
(C) Immunohistochemistry for iCP-Parkin in mouse cortex, striatum, and substantia nigra after intravenous (i.v.) injection of iCP-Parkin. Anti-Parkin antibody and anti-MAP2 
antibody for neurons. Scale bar, 10 m. (D) LC-MS/MS analysis detecting iCP-Parkin in the mouse brain. The mass spectrometry peak (filled with black color) shows an iCP-Parkin 
peptide (AVALIVVPALAPMIVFVR) containing aMTD 524. Time point: 0 and 30 min. (E) Quantified amounts of iCP-Parkin detected in brain samples of normal mouse by LC-MS/MS at 
varied time points (n = 5). Time point: 5, 15, and 30 min, and 1, 2, 4, 8, and 24 hours. *P < 0.01 versus 24 hours. Data in (B) and (E) are the means ± SD with Student’s t test, respectively.
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iCP-Parkin suppresses -synuclein accumulation
Sporadic PD is associated with structures known as Lewy bodies that 
contain pathological (oligomeric, filamentous, or phosphorylated) 
forms of -synuclein, -synuclein–interacting protein, synphilin-1, 
and Pael-R (G protein–coupled receptor 37) (20–23). To study the 
effects of iCP-Parkin on -synuclein aggregation, we used SH-SY5Y 
cells engineered to overexpress a green fluorescent protein (GFP)–
tagged -synuclein protein (designated TagGTP2--synuclein 
SH-SY5Y). Mitochondrial poisons, such as sodium arsenite and 
rotenone, stimulate the accumulation of insoluble, pathological forms 
of -synuclein (24), as we also observed (Fig. 4 and fig. S5); moreover, 
the process was suppressed by iCP-Parkin. Oligomeric and filamentous 
-synuclein were significantly decreased by 93 and 80% in the soluble 
fraction (Fig. 4B). iCP-Parkin significantly reduced pSer129--synuclein, 
Fig. 3. iCP-Parkin promotes mitophagy and mitochondria biogenesis in toxin-treated cells. (A) Cytoprotective action mechanism of iCP-Parkin by promoting 
mitophagy and mitochondria biogenesis. (B) Immunoprecipitation (IP) assay for analyzing the interaction between PINK1and iCP-Parkin after CCCP treatment in 
TagGFP2–-synuclein–SH-SY5Y cells. The representative data are presented, and the tests were carried out with three repetitions. IB, immunoblot. (C) Mitochondria were 
isolated from HAP1 Parkin WT cells treated with CCCP for 4, 12, and 24 hours. Western blot analysis was performed to detect iCP-Parkin. The level of iCP-Parkin was signifi-
cantly increased in CCCP-treated mitochondria compared with normal mitochondria (n = 3). (D) Mitochondria were isolated from Parkin KO HAP1 cells treated with CCCP for 
12 hours for ELISA. The amount of iCP-Parkin was significantly increased in the CCCP-treated group (n = 3). (E) Immunoprecipitation and Western blot analysis for analyzing 
the ubiquitination of Miro2 by iCP-Parkin using cell lysates from HeLa cells transfected with the indicated constructs and treated with CCCP and MG132 (20 M each) for 
6 hours in the presence or absence of iCP-Parkin. (F) Western blot analysis for detecting LC3B-II, an autophagy marker, in lysates from CCCP- or CCCP + iCP-Parkin–treated 
SH-SY5Y cells treated with chloroquine, an autophagy inhibitor. For quantification, the band intensity ratio of LC3B-II/LC3B-I in each group was normalized to that in the 
untreated control group (n = 3). (G) Representative confocal microscope images for detecting mitophagy increased by iCP-Parkin under CCCP treatment in HeLa cells 
(n = 19). (H) ELISA of the levels of mitochondrial proteins, COX1, and SDH-A in HeLa cells treated with either 30 M CCCP or 10 M iCP-Parkin as indicated (n = 4). Statistical 
comparisons were performed using Student’s t test. (I) Immunoprecipitation and Western blot analysis for analyzing the ubiquitination of PARIS by iCP-Parkin using cell 
lysates from HeLa cells transfected with the indicated constructs and treated with CCCP and MG132 (20 M each) in the presence or absence of i iCP-Parkin. (J) ATP levels 
were analyzed by an ATP Glo assay after cotreating SH-SY5Y cells with CCCP and Parkin recombinant proteins. iCP-Parkin recovered the ATP levels decreased by CCCP in 
a dose-dependent manner (n = 3). *P < 0.05 versus CCCP only. (K) iCP-Parkin also recovered the cellular ROS levels decreased by CCCP (n = 3). (L) Cell viability analysis using 
the CCK-8 assay in HeLa cells (n = 3). *P < 0.01 versus vehicle; **P < 0.05 versus CCCP only; ***P < 0.01 versus CCCP only. Scale bar, 10 m. Data in (C), (D), (G), (H), (J), (K), and (L) 
are the means ± SEM with Student’s t test. Data in (F) are represented as the means ± SEM, and statistics were analyzed by one-way ANOVA with post hoc Tukey’s test analysis.
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which was induced by treatment with sodium arsenite or rotenone, 
in both immunostaining (Fig. 4C) and Western blot analysis (Fig. 4D 
and fig. S5, I and J), as well as total -synuclein. In addition, iCP- 
Parkin significantly decreased apoptosis in sodium arsenite–treated 
cells (fig. S5, D and E). However, the C444S mutant failed to decrease 
pathological forms of -synuclein (fig. S5, F and H, also in the test 
using non–CP-Parkin) and did not inhibit apoptosis and cytotoxicity 
levels (fig. S5, E and G), presuming that iCP-Parkin has a cytoprotective 
action by using both enzymatic activity as an E3 ubiquitin ligase and 
cell permeability.
iCP-Parkin physically interacted with pSer129--synuclein and 
synphilin-1 in sodium arsenite–treated TagGTP2--synuclein 
SH-SY5Y cells, as assessed by coimmunoprecipitation concomitant 
with increases in total ubiquitination (Fig. 4E). In addition, iCP-Parkin 
enhanced substrate ubiquitination in cells overexpressing denoted 
substrates such as Pael-R and synphilin-1 (Fig. 4F and fig. S5, A and B).
Fig. 4. iCP-Parkin suppresses the accumulation of pathological -synuclein and has cytoprotective function in vitro. (A) Cytoprotective action mechanism of 
iCP-Parkin by reducing Lewy body proteins including pathological -synuclein. (B) Representative dot blot images showing a significant decrease in pathological -synuclein 
forms, such as oligomeric and filamentous, and -synuclein by iCP-Parkin in the soluble fraction at 8 hours (n = 3). (C) Immunofluorescence imaging of phosphorylated 
(pSer129) -synuclein (p--synuclein; denoted as red colorized signal). iCP-Parkin reduced p--synuclein aggregates induced by treatment with sodium arsenite. The 
green fluorescent signal indicates GFP-tagged -synuclein. The relative pixel intensity of the green fluorescent signal indicating a local concentration of GFP-tagged 
-synuclein protein was quantified using ImageJ software. The graph demonstrates semiquantification of the relative fluorescence intensity in images indicating 
p--synuclein–positive signals. Scale bar, 10 m (n = 3). (D) Representative Western-blotted image showing the reduction in neurotoxin-induced phosphorylated (pSer129) 
-synuclein and -synuclein aggregates in the insoluble fraction by iCP-Parkin (20 M). The representative data are presented, and the tests were carried out with three 
repetitions. (E) Immunoprecipitation assay with the soluble fraction demonstrating physical interactions between iCP-Parkin and phosphorylated (pSer129) -synuclein or 
synphilin-1 in TagGFP2–-synuclein–SH-SY5Y stable cells (4 hours). Note that the same cell lysates were used for immunoprecipitation and input immunoblot simultaneously. 
Global ubiquitination was also increased by iCP-Parkin. The representative data are presented, and the tests were carried out at various time points (2 to 8 hours). 
(F) Immunoprecipitation assay for ubiquitination of synphilin-1 by iCP-Parkin in HEK293T cells. The representative data are presented, and the tests were carried out with 
two repetitions. (G) Western blot analysis showing a dose-dependent decrease in cleaved caspase-3 by iCP-Parkin at 8 hours. (H) CellTiter-Glo analysis showing a dose- 
dependent increase in cell viability by iCP-Parkin at 24 hours. Cell viability was analyzed using CellTiter-Glo analysis after cotreating the cells with different doses of 
iCP-Parkin and 20 M sodium arsenite. *P < 0.0001 versus sodium arsenite only. Data in (B), (C), and (H) are expressed as the means ± SEM with Student’s t test (n = 3).
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Last, iCP-Parkin suppressed the toxicity of sodium arsenite in 
a dose-dependent manner with concomitant reductions in cleaved 
caspase-3, an apoptosis mediator (Fig. 4G). Furthermore, iCP-Parkin 
treatment showed dose-dependent cytoprotective activity against 
sodium arsenite in TagGTP2--synuclein SH-SY5Y cells (Fig. 4H). 
The ability of iCP-Parkin to suppress poison-induced accumulations 
of pathological forms of -synuclein was sensitive to both proteasome 
[N-carbobenzyloxy-l-leucyl-l-leucyl-l-leucinal (MG132)] and autophagy 
(bafilomycin A1) inhibitors (fig. S5, C, K, and L), implicating that 
the ubiquitin proteasome system and autophagy-lysosome pathway 
systems are related to iCP-Parkin action (Fig. 4A).
Efficacy of iCP-Parkin in toxin-induced PD animal models
The neuroprotective activity of iCP-Parkin was tested in a 6-hydroxy-
dopamine (6-OHDA)–induced PD mouse model (25). Saline or 4 g 
of 6-OHDA was stereotaxically injected into the right medial forebrain 
bundle (MFB; day 0), and iCP-Parkin (30 mg/kg) or non–CP-Parkin 
was administered on days 4, 5, and 6 (Fig. 5A). 6-ODHA induced 
significant motor impairment (>60-fold) after 3 days compared 
with control groups based on the rotation test (Fig. 5B), and motor 
test was carried out on days 0 and 5 to 9 using the pole test. iCP-Parkin 
treatment led to steady improvements in descent times (to 82 and 
71% of the control groups by days 8 and 9, respectively; whereas 
non–CP-Parkin had no effect Fig. 5C). Motor impairment was 
accompanied by repression of TH expression that was partially 
restored (74% recovery) by iCP-Parkin expression in the injected 
hemisphere as compared with the uninjected, contralateral side 
(Fig. 5, D to F). TH, the rate-limiting enzyme in DA biosynthesis, 
correlates with DA expression and provides a marker for dopaminergic 
neurons. More frequent administrations of iCP-Parkin (three times 
per week compared with once a week) further restored TH expression 
but without further improvements in motor function (fig. S6, A to C).
Considering the role of Parkin in mitophagy and mitochondrial 
biogenesis, we tested whether mitochondrial protein levels changed 
in response to 6-OHDA and iCP-Parkin treatment. As shown in 
fig. S6D, the levels of COX4 and voltage-dependent anion channel 1 
(VDAC1) were reduced in the 6-OHDA–induced PD model and 
mitigated by iCP-Parkin treatment. These results suggest that the 
normal cellular Parkin-mitophagy pathway is overwhelmed by 
6-OHDA–induced mitochondrial damage, and iCP-Parkin reinforces 
the Parkin-mitophagy response.
Similar studies examined the effectiveness of iCP-Parkin in the 
6-OHDA rat PD model (26). iCP-Parkin (5, 15, or 30 mg/kg) was 
intravenously administered three times per week for 4 weeks starting 
on the third week after unilateral 6-OHDA injection into the striatum 
(Fig. 5G). PD disease induction was confirmed by using the rotation 
test, where 6-ODHA–injected animals showed significant motor deficits 
(more than 400-fold) compared with the diluent group (Fig. 5H). 
Motor deficits were recovered by iCP-Parkin in a dose-dependent 
manner (46, 77, and 100% compared with controls) (Fig. 5I). TH 
expression (Fig. 5J) and plasma DA levels (Fig. 5K) both declined in 
6-OHDA–lesioned rat, while TH expression was largely restored in 
the striatum and substantia nigra (80 and 66%, respectively) by 
iCP-Parkin treatment (Fig. 5, L and M) along with improvements in 
motor function (89%). By contrast, motor functions in mice treated 
with cell-permeable C444S Parkin mutant protein continued to 
decline (by 20%) by the rotarod test (fig. S6, E and F).
Similar anti-Parkinsonian effects were also observed in mice 
treated with the mitochondrial poison MPTP and iCP-Parkin 
under a variety of conditions (fig. S7, A, E, H, and K). In all cases, 
iCP-Parkin treatment led to significant recovery of motor deficits 
as assessed by the gait [90% (stride) and 79% (sway); fig. S7B], 
swim (51%; fig. S7D), wire (86%; fig. S7J), and rotarod tests (93%; 
fig. S7L). Motor recovery was accompanied by 83% recovery of 
urine DA levels (fig. S7C) and restoration of TH expression (fig. S7, 
F, G, and I).
Efficacy of iCP-Parkin in -synuclein–induced  
PD mouse model
Because -synuclein is linked to sporadic PD, the most common 
presentation of the human disease (27), iCP-Parkin was tested in an 
-synuclein–induced PD mouse model. Mice infected intracranially 
with an adeno-associated virus (AAV) -synuclein expression vector 
experienced accumulations of soluble and insoluble -synuclein 
forms after 4 weeks and 82% loss of DA-expressing neurons in the 
substantia nigra by week 8 (27). In our study, the infected mice 
began to show motor deficits 5 weeks postinitiation, and the defects 
became prominent by week 8 (Fig. 6 and fig. S8), indicative of late- 
early to middle-stage PD pathology.
Mice treated with iCP-Parkin (30 mg/kg, three times weekly for 
4 weeks starting at week 8; Fig. 6A) displayed improved motor function 
as assessed by the rotarod test even in the first week, and their motor 
function improved to 90% of unlesioned controls by treatment 
week 4 (Fig. 6B). Motor deficits were accompanied by loss of 
TH-positive neurons in the substantia nigra, and these losses were 
abrogated by iCP-Parkin (Fig. 6C), which was also observed by 
immunostained sections of the striatum (fig. S8B). Furthermore, 
iCP-Parkin reduced -synuclein levels in TH+ neurons by 72 
and 79% in the substantia nigra and the striatum, respectively 
(Fig. 6, D and E), consistent with the response observed in NeuN- 
positive cells (a pan-neuronal marker; fig. S8, C and E). In another 
test (Fig. 6, F to M) with a different protocol (10 mg/kg, three times 
per week), iCP-Parkin treatment led to progressive recovery of 
motor function (31, 54, and 72% at 9 to 11 weeks, respectively) in 
the pole test (Fig. 6G). TH expression was significantly recovered 
(63%), and -synuclein was significantly decreased (68%) by Western 
blot analysis (Fig. 6H), consistent with immunostaining data (Fig. 6I).
Protein aggregates visualized by thioflavin S staining were also 
significantly reduced (76%) in the substantia nigra (Fig. 6J), also 
similarly observed in the striatum (fig. S8D), and reduced the levels 
of pathological [filamentous/aggregated (Fig. 6K and fig. S8H) and 
phosphorylated (Fig. 6, L and M)] -synuclein and glial fibrillary 
acidic protein (GFAP; fig. S8G) in the striatum and/or substantia 
nigra regions. In addition, when iCP-Parkin (30 or 50 mg/kg, 
one time at 8 weeks) was administered after the injection of 
AAV–-synuclein to the right side of the brain, iCP-Parkin recovered 
behavior defects by 100% in the beam test (fig. S6, G and H).
DISCUSSION
Mechanism-based drug development requires unambiguous evidence 
of therapeutic action consistent with targeting known biochemical 
pathways or associated molecular partners. PD poses several significant 
challenges to this drug discovery paradigm: (i) The underlying disease 
mechanism(s) is not well understood, (ii) existing animal models do 
not fully restage the pathophysiology of sporadic PD, and (iii) the 
disease is diagnosed after the onset of motor symptoms, at which 
point it is not clear if PD progression can be halted or reversed.
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The present study describes advances in each of these areas. 
Specifically, we developed sequence-optimized aMTDs to enable 
efficient systemic delivery of protein therapeutics. The technology 
was used to evaluate Parkin as a potential drug in the treatment 
of PD. Intracellular delivery of iCP-Parkin into DA neuronal cells 
in vitro or in vivo suppressed neuronal toxicity by removing 
damaged mitochondria and/or reducing pathological -synuclein. 
In addition, TH-positive cells in the striatum and the midbrain were 
restored, DA expression was enhanced, and gross motor function was 
recovered. This outcome suggests that Parkinsonian motor deficits may 
be reversible and that iCP-Parkin has therapeutic potential as a 
PD-modifying agent, which may overcome the critical limitation of 
PD symptom–relieving drugs such as l-3,4-dihydroxyphenylalanine 
(l-DOPA).
Fig. 5. iCP-Parkin ameliorates behavioral and molecular defects in 6-OHDA–induced PD animal models. (A to F) Efficacy of iCP-Parkin in a 6-OHDA–induced PD 
mouse model. (A) Schematic diagram of the experimental protocol. 6-OHDA (4 g per head) was injected into the right side of the MFB. (B) Rotation test for confirming 
PD modeling at 3 days after 6-OHDA unilateral injection. (C) Pole test. After measuring the time to climb down a pole, raw data were converted into relative behavior 
activity based on the time of untreated control as 100%.  *P < 0.05 versus 6-OHDA  only. (D and E) Western blot analysis of TH expression (D) and graph of relative TH 
expression quantified using ImageJ (E) [n = 3, except iCP-Parkin (n = 6)]. Samples were collected 13 days after 6-OHDA treatment. L and R indicate the left and right sides of the 
brain, respectively. (F) Representative fluorescence imaging of TH expression in the substantia nigra. The fluorescence-based immunohistochemistry was performed to 
detect TH-positive dopaminergic neurons in the substantia nigra/ventral tegmental area. Scale bar, 200 m (n = 3). (G to M) Efficacy of iCP-Parkin in a 6-OHDA–induced 
PD rat model. (G) Schematic diagram of the experimental protocol. Different doses of iCP-Parkin were intravenously injected three times per week for 4 weeks from 
2 weeks after injecting 6-OHDA into the striatum on the right side of the brain. (H) Rotation test for confirming PD modeling at 2 weeks after 6-OHDA unilateral injection. 
(I) Rotarod test. Relative behavior activity is based on the value of the diluent control as 100% (n = 10 to 12). *P < 0.05 versus 6-OHDA only; **P < 0.01 versus 6-OHDA  only. 
(J) Western blot analysis of TH expression. L and R indicate the left and right sides of the brain (n = 4). (K) Recovery of plasma dopamine levels by iCP-Parkin, as determined 
by ELISA. (L) TH expression in the striatum as assessed by fluorescence immunostained brain sections. The graph indicates the relative R/L ratios of fluorescence intensity 
compared with the R/L ratio in unlesioned (diluent) animals (set to 1). Scale bar, 200 m (five to seven sections per animal, n = 5). *P < 0.05 versus 6-OHDA only; 
**P < 0.01 versus 6-OHDA only. (M) Fluorescence immunohistochemistry for detecting TH+ dopaminergic neurons in the substantia nigra. The graph indicates stereological 
counting of TH+ dopaminergic neurons in the substantia nigra. Scale bar, 200 m.  *P < 0.05 versus 6-OHDA only. Data in (B), (C), (H), and (I) are the means ± SEM. Data in 
(E), (L), (K), and (M) are the means ± SD. The P values were analyzed by one-way ANOVA with post hoc Tukey’s test.
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Other hydrophobic sequences have been empirically found to 
enhance the delivery of protein cargos, including Parkin, into cells. 
However, the prior technology that suffered from two limitations is 
now addressed by TSDT. First, we identified six critical sequence 
motifs (critical factors) that, when satisfied by an aMTD sequence, 
enhanced protein delivery by an average of 13-fold compared with 
previous nonoptimized sequences. Second, protein SDs were used to 
enhance recombinant protein solubility. In all, aMTD development 
tested 19 aMTD sequences and 2 SDs—a process we have found to 
be effective in developing other cell-permeable proteins.
Fig. 6. iCP-Parkin recovers behavioral and biochemical defects in AAV–-synuclein–induced PD animal models. (A) Schematic diagram of the experimental protocol 
in the AAV–-synuclein–induced PD mouse model. iCP-Parkin (30 mg/kg) was intravenously injected three times per week for 4 weeks from 8 weeks after injecting 
AAV–-synuclein into the right side of the brain (A to E). (B) Rotarod test. After recording the time walking on the rod, raw data were converted into relative behavior activity 
based on the time of diluent group as 100% (n = 10 to 12). #P < 0.05 versus diluent; *P < 0.05 versus AAV--Synuclein only. (C) Dopaminergic neurons were reduced in the 
group injected with AAV–-synuclein compared with the normal group and confirmed the protection of dopaminergic neurons increased in the group injected with iCP-Parkin in 
the substantia nigra. Scale bar, 100 m. (D and E) Quantitative graphs showing the relative fold change of -synuclein level in the substantia nigra (left) and the striatum (right) 
measured by using ELISA (n = 7). (F) Schematic diagram of the experimental protocol in the AAV–-synuclein–induced PD mouse model. iCP-Parkin (10 mg/kg) was intrave-
nously injected three times per week for 4 weeks from 8 weeks after injecting AAV–-synuclein into the right side of the brain (F to M). (G) Pole test. After measuring the time 
to climb down a pole, raw data were converted into relative behavior activity based on the time of the untreated control group as 100%. The data are presented as the 
means ± SEM, and the P values were determined by a post hoc Tukey’s test after one-way ANOVA. The number sign (#) and asterisks (*) indicate comparisons between diluent 
and AAV–-synuclein and between AAV–-synuclein and AAV–-synuclein with iCP-Parkin, respectively. *P < 0.05 versus AAV--Synuclein only. (H) Western blot analysis of TH 
and -synuclein (n = 3).  (Graph on left): **P < 0.01 versus AAV--Synuclein only. (Graph on right): *P < 0.05 versus AAV--Synuclein only. (I) Immunohistochemistry for detecting 
TH expression levels in substantia nigra. Scale bar, 100 m. (J) Confocal laser scanning microscopy of thioflavin S–stained sections from the substantia nigra (n = 3). (K) Immuno-
histochemistry for detecting the expression levels of filamentous -synuclein in substantia nigra. (L) Fluorescence coimmunohistochemistry and confocal laser scanning mi-
croscopy showing -synuclein filament aggregate and pSer129--synuclein in the substantia nigra. Note that iCP-Parkin significantly removes pSer129--synuclein+ -synuclein 
filament aggregates. Arrowheads demonstrate two signal double-positive -synuclein species. Scale bar, 20 m. (M) Western blot analysis for detecting pSer129--synuclein 
in brain samples. The representative data are presented (n = 3). The level of pSer129--synuclein increased by -synuclein overexpression was significantly eliminated by 
iCP-Parkin administration. Data in (B), (D), (E), (G), (H), and (J) are the means ± SEM, and statistics were analyzed by one-way ANOVA with post hoc Bonferroni test.
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Four of the critical factors—length, hydrophobicity, -helical 
moment, and internal proline—provide unbiased support for a 
mechanism of protein uptake suggested by structural studies of 
membrane-spanning peptides and biophysical interactions between 
peptides and model membranes (28, 29). Briefly, the 12–amino acid 
aMTDs are predicted to adopt shorter, bent confirmations in an 
aqueous environment (due to an internal proline and the tilt angle 
between amino acids) and a longer, more linear conformation after 
insertion into the hydrophobic environment of the lipid bilayer 
(due to reduced helix bending by proline and increased tilt angles). 
The lengthening should then increase hydrophobic mismatch and 
favor exit from the membrane, presumably in either direction. 
Consistent with this model, aMTD-mediated protein uptake appeared 
to involve direct membrane penetration. Uptake did not require 
ATP, cell surface proteins, microtubule function, or endocytosis, 
but it required an intact and fluid membrane. Last, cell-to-cell 
transfer of iCP-Parkin implies bidirectional transport across the 
plasma membrane, consistent with a direct penetration model. 
Bidirectional transport would also account for extensive tissue 
penetration by iCP-Parkin in vivo, including the ability to cross the 
BBB. The current study demonstrating the neuroprotective effect of 
iCP-Parkin in deep brain including the striatum was achieved by 
the BBB permeability of iCP-Parkin, as well as in vivo systemic 
delivery, which was confirmed by a wide spectrum of quantitative 
and qualitative methodologies including LC-MS/MS, Western blot, 
ELISA, and cell-specific immunostaining of various brain regions.
A key challenge in medicine is the development of therapeutic 
agents with the desired activity, specificity, and bioavailability. In 
principle, therapeutic proteins have two advantages compared with 
conventional small-molecule drugs. First, the proteins interact across 
larger surfaces and, therefore, have greater specificity and fewer 
off-target effects. Second, whereas protein-protein interactions have 
been evolutionarily optimized, many proteins may not be “druggable” 
because they lack of small-molecule binding sites capable of producing 
the desired changes in protein activity.
The addition of an aMTD sequence greatly extended the persistence 
of recombinant Parkin and GFP proteins in vivo. We speculate that 
intracellular proteins transferred from cell to cell are sequestered 
from the blood and, therefore, are not excreted as rapidly as cell- 
impermeable, blood-borne proteins. aMTD sequences may provide 
an effective means to extend the half-lives of other therapeutic 
proteins, even proteins (e.g., antibodies) that do not require intracellular 
delivery. We show that the TSDT platform can be used to deliver 
Parkin protein systemically with a wide tissue distribution like most 
small-molecule drugs. Even so, iCP-Parkin became concentrated in 
the vicinity of damaged mitochondria, suggesting that the protein 
may be selectively retained in cells where it is biochemically engaged. 
This mechanism-specific cell targeting could help explain why 
iCP-Parkin, like Parkinson protein 2 (PARK2) transgenes, appear 
to be well-tolerated despite widespread tissue distribution.
iCP-Parkin appeared to be in a constitutively active, open con-
formation, either as a result of the refolding step during purification 
or by the attachment of the amino-terminal aMTD sequence (15). 
Nevertheless, iCP-Parkin recapitulated features of endogenous 
Parkin in the damage-induced mitophagy pathway (30). Internalized 
iCP-Parkin, colocalized with both PINK1 and mitochondria undergoing 
mitophagy, increased the ubiquitination of mitochondrial Parkin 
substrates and suppressed apoptosis induced by mitochondrial poisons. 
This suggests that iCP-Parkin reinforces endogenous cellular Parkin 
levels that are otherwise insufficient to protect cells against acute 
mitochondrial poisoning or the chronic damage associated with 
insoluble -synuclein. Overall, the levels of cytoprotection achieved 
by iCP-Parkin were matched to those achieved by enforced PARK2 
gene expression in both neuronal cell lines and transgenic animal 
models (3, 8–10, 13, 31–34). However, the cytoprotective benefits of 
iCP-Parkin treatment were accrued within hours, even when the 
protein was delivered after cell damage.
In addition to removing damaged mitochondria by mitophagy 
(as evidenced by colocalization of mitochondria and lysosomes, and 
reduced levels of reactive oxygen, ATP, and mitochondrial proteins), 
iCP-Parkin enhanced mitochondrial biogenesis (based on increased 
ATP and mitochondrial protein levels). Once again, the behavior of 
iCP-Parkin was consistent with normal Parkin function, which is 
thought to promote mitochondrial biogenesis by ubiquitinating 
PARIS, a transcriptional repressor of PGC-1, a coactivator of 
transcription factors, such as NRF1 and NRF2 (35, 36). PINK1 
interacts with and phosphorylates PARIS to regulate its ubiquitination 
and removal by Parkin (36). Likewise, PINK1 was required for PARIS 
ubiquitination by iCP-Parkin.
iCP-Parkin treatment reduced the levels of aggregated -synuclein 
in cells by an unknown mechanism. Like Parkin, iCP-Parkin 
ubiquitinates synphilin-1 and Pael-R (but not -synuclein), which 
are known Parkin substrates and accumulated in Lewy bodies together 
with -synuclein (22, 23). iCP-Parkin could influence Lewy body 
formation or clearance at the level of protein turnover. Alternatively, 
iCP-Parkin could suppress processes (e.g., mitochondrial dysfunction 
and/or ROS production) that generate pathological forms of 
-synuclein or promote their aggregation.
Our results are consistent with a model in which mitochondrial 
poisons and aggregated -synuclein suppress DA expression by 
down-regulating TH, the rate-limiting enzyme in DA biosynthesis. TH 
is subject to multiple levels of transcriptional and posttranscriptional 
regulation (37), and reversible loss of TH expression may function 
as a normal self-protective mechanism in times of neuronal stress. 
This would relieve dopaminergic neurons of the additional burden 
of endogenously produced and toxic DA metabolites [e.g., 1-methyl- 
6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol) and 3,4- 
dihydroxyphenylacetaldehyde; (38, 39)], as illustrated by the ability 
of 6-OHDA to induce PD symptoms. The self-protection model 
implies that some loss of TH staining during PD progression may 
not initially be caused by neuronal death and therefore might be 
reversed. Together, this would provide a window of opportunity for 
therapeutic interventions to restore DA expression even after the 
onset of motor symptoms, as observed in animals treated with 
iCP-Parkin.
MATERIALS AND METHODS
Expression and purification of Parkin recombinant proteins
The optimized iCP-Parkin coding sequence was cloned into pET-
26b(+) vector. The protein was expressed in Escherichia coli BL21- 
CodonPlus (DE3)-RIL cells using modified TB media (for 1 liter: 
10 ml of glycerol, 24 g of yeast extract, 12 g of soy peptone, 9.4 g of 
K2HPO4, and 2.2 g of KH2PO4). The cells were grown to an OD600 
(optical density at 600 nm) of 3 to 4 and induced for 3 to 4 hours with 
0.5 mM isopropyl--d-thiogalactopyranoside (IPTG). Subsequently, 
the cells were harvested by centrifugation (8000 rpm, 4°C, 10 min) 
when OD600 value was approximately 12. Fermentation was done 
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using a 50-liter fermenter with agitation speed of 250 to 300 rpm 
and constant aeration rate of 0.5 aeration volume/media volume/
minute (VVM) at 37°C. The harvested cells were disrupted by sonica-
tion (amplitude of 60%, 5-s sonication/5-s rest interval) for 30 min 
in lysis buffer {50 mM 3-[cyclohexylamino]-1-propanesulfonic acid 
(CAPS) (pH 10.5) and 1.0 M NaCl}. Afterward, inclusion body was 
isolated by centrifugation (2500g for 30 min at 4°C) and was washed 
one time with lysis buffer. The washed inclusion body was dissolved 
in unfolding buffer [8 M urea, 50 mM CAPS (pH 10.5), 0.5% CHAPS, 
and 10 mM dithiothreitol (DTT)] at room temperature (RT) for 
1 hour. Then, the sample was incubated at RT for 3 hours with addi-
tion of 0.1 mM ZnCl2. The unfolded protein was poured into re-
folding buffer [0.5 M arginine, 150 mM NaCl, 100 mM non-detergent 
sulfobetaines (NDSB), 50 mM tris, 2 mM reduced glutathione, 
0.2 mM oxidized glutathione disulfide, and 1 mM DTT (pH 8.0)]. 
Once the refolding process was completed for 48 hours, ion exchange 
chromatography (IEX) was conducted as a capturing chromatography 
with the AKTA Purifier FPLC (fast protein liquid chromatography) 
System (GE Healthcare). Briefly, Q-Sepharose high-performance 
column was equilibrated and flowed with protein solution in 
equilibrium buffer [50 mM tris (pH 8.0), 0.1 M NaCl, and 1 mM 
DTT]. Subsequently, the column was washed with the equilibrium 
buffer and washing buffer [50 mM tris (pH 8.0), 0.17 M NaCl, and 
1 mM DTT) to remove the unbound proteins. Then, the proteins 
were eluted with elution buffer [50 mM tris (pH 8.0), 0.35 M NaCl, 
and 1 mM DTT). After IEX chromatography, size exclusion 
chromatography was performed by using a Superdex 200. After the 
purification, the protein was concentrated using Pellicon 2 and 
Sartocon slice Ultrafiltration Unit (Sartorius). Endotoxin was removed 
using EndoTrap high-definition (HD) column (Hyglos GmbH). 
Last, proteins were dialyzed against a storage buffer [50 mM tris and 
150 mM NaCl (pH 8.0)] using Sephadex G-25 column (GE Healthcare).
Analysis of protein uptake by cultured cells
Recombinant Parkin proteins were conjugated to 5/6-FITC according 
to the manufacturer’s instructions (Sigma-Aldrich). SH-SY5Y cells were 
treated with 10 M FITC-labeled recombinant proteins for 1 hour at 
37°C, washed three times with cold phosphate-buffered saline (PBS), 
and treated with proteinase K (10 g/ml) for 20 min at 37°C to remove 
surface-bound proteins, and internalized proteins were visualized by 
flow cytometry using a Guava easyCyte 8 instrument (Millipore).
C2C12 cells were treated with different agents to assess the mecha-
nism of protein uptake, as follows: (i) proteinase K (10 g/ml) for 10 min; 
(ii) 10 M antimycin in the presence or absence of 1 mM ATP for 2 hours; 
(iii) 10 mM EDTA for 1 hour; (iv) incubation on ice (or at 37°C) for 15, 
30, or 60 min; (v) 20 M Taxol for 30 min; (vi) 5 mM amiloride for 30 min; 
(vii) 3 M chlorpromazine for 30 min; and (viii) 5 mM methyl-- 
cyclodextrin for 30 min. The cells were then incubated with 10 M 
FITC-labeled proteins for 1 hour at 37°C, washed three times with 
ice-cold PBS, treated with proteinase K (10 g/ml for 20 min at 37°C) 
to remove surface-bound proteins, and analyzed by flow cytometry.
To assess cell-to-cell protein transfer, donor C2C12 cells were 
treated with 10 M FITC-conjugated iCP-Parkin and non–CP-Parkin 
proteins in serum-free DMEM medium for 2 hours at 37°C followed 
by washing, and mixed with mouse RAW264.7 cells (recipient cells) 
labeled with (PE) rat anti-mouse CD14 antibody (BD Biosciences, 
San Jose, CA) for 2 hours at 37°C in a 5% CO2 incubator. Cell-to-cell 
protein transfer represented by FITC/PE double-positive cells, was 
monitored by a Guava easyCyte Benchtop Flow Cytometer (Millipore).
Primary neuronal culture and double immunocytochemistry
Institute of Cancer Research (ICR) pregnant females (13.5 days) were 
euthanized by cervical dislocation to isolate primary neurons. The 
isolated ventral mesencephalon from the fetuses was pooled, and 
single primary cortical neuronal cells were obtained by incubation with 
Accutase (Thermo Fisher Scientific) for 15 min at 37°C. Neurobasal 
medium (Thermo Fisher Scientific) containing l-glutamine, B-27 
supplement (Thermo Fisher Scientific), B-27 plus supplement 
(Thermo Fisher Scientific), 10% fetal bovine serum (FBS), and 
ascorbic acid solution were used for cell culture. The cells were plated 
at a density of 1.5 × 104 cells/cm2 in the poly-d-lysine/laminin-coated 
plates and further cultured at 37°C in a 5% CO2 incubator for 7 days. 
For cell permeability test, primary neuron was seeded 0.5 × 105 per 
well in the 12-well plate. iCP-Parkin (10 M) and 6-OHDA (30 M; 
Sigma-Aldrich) were cotreated for 2 and 24 hours. For immuno-
staining, ß-III tubulin (Abcam, USA, catalog no. ab18207) and Parkin 
(Novus Biologicals, catalog no. NBP2-29838) antibodies were used 
as primary antibodies.
Systemic protein delivery of Parkin proteins to the brain 
and other tissues
Several methods were used to investigate the delivery of recombinant 
proteins to the brain and other tissues. (i) Delivery of FITC-conjugated 
proteins was visualized by fluorescence microscopy in cryosections 
(30 m). Alternatively, minced tissues were passed through a 70-m 
nylon cell strainer (BD Biosciences), and the cell suspensions 
were analyzed by flow cytometry with a Guava easyCyte instrument 
(Millipore). For immunostaining, MAP2 antibody (Abcam, ab32454) 
was used for detecting neurons. (ii) For Western blot analysis, tissue 
lysates were prepared after perfusion with PBS to remove residual 
blood within the tissues and stored at −80°C. (iii) Signature peptides 
from the aMTD segment of iCP-Parkin were detected by LC-MS/
MS analysis of brain tissues [under contract with Envigo (Huntingdon, 
UK)]. Briefly, brain lysates were digested using two different digestion 
kits, SMART Digest (Thermo Fisher Scientific) and ProteinWorks 
(Waters), and peptides were separated on an ACE UltraCore SuperC18 
column (Advanced Chromatography Technologies) with an aceto-
nitrile gradient and analyzed on a Sciex API 6500+ mass spectrometer 
(SCIEX). Ions generated by the signature peptide carried charges 
of (M+2H)2+ and (M+3H)3+ and were detected at 940.4 and 627.4 Da, 
respectively. (iv) Last, levels of iCP-Parkin protein in the brain 
and serum were determined by an ELISA kit (KOMA BIOTECH). 
Horseradish peroxidase (HRP) reaction products were measured at 
450 nm with a microplate reader (Synergy H1, BioTek Instruments).
Cells and antibodies related to in vitro mechanism studies
SH-SY5Y and TagGFP2--synuclein SH-SY5Y cells were commercially 
acquired (Innoprot). HAP1 and Parkin-KO human near-haploid 
(HAP)1 cells were obtained from the Horizon Discovery. NIH3T3, 
RAW264.7, and C2C12 cells were obtained from the American Type 
Culture Collection (ATCC). Cell viability was evaluated by CellTiter- 
Glo cell viability assay (Promega) and quantified using a luminometer 
(Turner Designs) or luminescence plate reader (Synergy H1, BioTek 
Instruments). Apoptosis was assayed by annexin V/7-aminoactinomycin 
D (7-AAD) staining as directed by the supplier (BD Biosciences) and 
analyzed by flow cytometry on a Guava easyCyte 8 instrument (Mil-
lipore). To visualize mitochondria and mitochondria undergoing mitophagy, 
cells were stained with 1 mM Lyso Dye (Dojindo Molecular Technol-
ogies) and 100 nM Mtphagy Dye (Dojindo Molecular Technologies), 
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respectively. Mitochondrial biogenesis was monitored by the Mito-
Biogenesis In-Cell ELISA Kit (Abcam, ab110217). Measurements of 
intracellular ROS used the Abcam ROS detection kit (Abcam, ab113851).
Procedures for Western blot analysis and immunostaining of cells 
and tissues are described previously (13). Soluble and insoluble cell 
fractions were prepared as described elsewhere (40). For dot blot analysis, 
cell lysates (1.5 g of protein) were bound to nitrocellulose membranes 
with a Bio-Dot microfiltration apparatus (Bio-Rad) by gravity filtration. 
This passive filtration is necessary for quantitative antigen binding.
The ability of iCP-Parkin to ubiquitinate or physically interact 
with specific proteins was studied by immunoprecipitation Western 
blot analysis in HeLa, human embryonic kidney (HEK) 293T, or 
SH-SY5Y cells transiently transfected with plasmids expressing 
HA-tagged human ubiquitin, Myc-Miro2 (Addgene, 47891), Myc-
Flag-PARIS (OriGene, RC209784), Myc-PINK1 (Addgene, 13314), 
Myc-Mfn1 (Addgene, 23212), Myc-Mfn2 (Addgene, 23213), Flag-Peal-R 
(OriGene, Rc208054), or Flag-synphilin (GenScript, OHu19245D). 
Cells were transfected using Lipofectamine 3000 (Thermo Fisher 
Scientific) according to the manufacturer’s instructions and were treated 
or not with mitochondrial poisons (sodium arsenite, Sigma-Aldrich) 
and iCP-Parkin depending on the experiment and lysed in IP lysis 
buffer [Thermo Fisher Scientific, 1% Triton X-100 in 1× PBS buffer 
(pH 7.4)] supplemented with EDTA-free protease inhibitor mix 
(Roche). Proteins, normalized by Bradford assay, were immuno-
precipitated using the relevant antibodies. Immune complexes were 
recovered using Protein G Sepharose 4 Fast Flow (GE Healthcare) 
and analyzed by Western blot analysis.
Antibodies were purchased from the following sources and used 
as specified by the supplier: Novus Biologicals (Parkin, NBP2-29838, 
epitope: 399-465 A/a); Merck Millipore (Parkin, MAB5512; TH, 
A5152); Ubiquigent (pSer65-Parkin); Cell Signaling Technology 
(PINK1, ab75487; LC3B, 2775; cleaved caspase-3, 9664; HA tag, 
3724S; Myc tag, 2272; and HRP-conjugated anti-mouse secondary 
antibody, 7076S); Sigma-Aldrich (-actin, A3854); ENZO Life 
Sciences (ubiquitin, BML-PW-8810-0500); BioLegend (PINK1, 
846202); ABclonal (Abclone, SDB, clone 7C1); Thermo Fisher 
Scientific (anti-rabbit Alexa 488, A-11034; anti-chicken Alexa 568, 
A11041); Abcam (-synuclein, ab138501; pSer129 -synuclein, 
ab51253; GFAP, ab-53554); MBL Life Sciences (Myc tag, M192-3); 
and Vector Laboratories (biotinylated rabbit anti-rat, BA-1000). 
Proteins in Western blots were visualized by chemiluminescence 
(SuperSignal West Femto, Thermo Fisher Scientific) and scanned 
using a ChemiDoc instrument (Bio-Rad). MG132, a proteasome 
inhibitor, was added to some treatment groups to stabilize ubiquitinated 
proteins in the immunoprecipitation tests.
For in vitro studies relevant to pathological -synuclein model, 
the TagGFP2--synuclein SH-SY5Y cell line was seeded, and iCP- 
Parkin protein at designated concentrations and durations was 
cotreated with a neurotoxin, sodium arsenite (10 or 20 M). Inhibitors 
to block proteasome or autophagy inhibitors were used with designated 
concentrations as follows: proteasome (MG132) and autophagy 
(chloroquine or bafilomycin A1).
PD animal models
All in vivo experiments were performed in a blinded manner. Usually, 
one researcher would randomize the animals and slides, and another 
would analyze them. The following criteria were developed to remove 
any possible outliers from animal groups before treating iCP-Parkin; 
animals that did not recover from the surgery, exhibited more than 
30% body weight loss, or had normal rotation test outcomes after 
inducing the PD model were excluded from the group for further 
analysis. All behavior tests were repeated three times per animal for 
each experimental date, and numerous different PD animal models 
were used for the iCP-Parkin efficacy study.
iCP-Parkin was tested in several animal models for the ability to 
prevent and/or restore PD-related motor symptoms. In each model, the 
onset of motor symptoms was verified by an apomorphine rotation test 
(41) before starting iCP-Parkin treatments. Animals were injected 
subcutaneously with apomorphine (0.1 mg/kg) (freshly dissolved in 
0.1% ascorbic acid solution and kept on ice in the dark before use) and 
judged to be symptomatic if side-biased rotation of lesioned mice turns 
faster than a rate of ~60 turns over 20 min. Parkin proteins were 
administered intravenously at the times and doses as described in 
the text, and changes in motor function were monitored as de-
scribed below.
6-OHDA–induced PD mouse model
C57BL/6 mice (9 to 13 weeks, male) were anesthetized by a 1:1 mixture 
of Zoletil:Rompun (Bayer) diluted 1:10 in saline, positioned onto 
a stereotaxic apparatus, and injected with 4 g of 6-OHDA (Sigma- 
Aldrich) dissolved in 0.8 l of 0.01% ascorbic acid (Sigma-Aldrich) 
at a rate of 0.2 l/min into the MFB at the following coordinates 
(relative to the bregma): anterior-posterior (AP) = −1.2 mm, medial- 
lateral (ML) = −1.2 mm, and dorsal-ventral (DV) = −4.75 mm (from 
the dura) with a flat skull position. Control mice were injected with 
0.01% ascorbic acid solution alone.
AAV–Asynuclein–induced PD mouse model
Anesthetized C57BL/6 mice (8 weeks, male) were stereotaxically 
injected with the human WT -synuclein AAV/DJ vector (1 l of 
1.4 × 1013 genome copies (GC)/ml titer; Research Animal Resource 
Center, KIST) at a rate of 0.5 l/min into the substantia nigra at 
the following coordinates (relative to the bregma): AP = −3.1 mm, 
ML = −1.2 mm, and DV = −4.00 mm (from the dura) with a flat 
skull position. The control group was injected with saline.
6-OHDA–induced PD rat model
Anesthetized male Sprague-Dawley rats (~230 g) were injected with 20 g 
of 6-OHDA (5 g/l) at a rate of 0.5 l/min into the striatum at the 
following coordinates (relative to the bregma): AP = −1.0 mm, ML = −2.8 mm, 
and DV = −6.0, 5.5, 5.0, and 4.4 mm (from the dura) with a flat skull posi-
tion. The control group was injected with 0.01% ascorbic acid solution.
Motor function analysis
Pole test
Mice were placed on the top of a vertical pole (50-cm length with 
1-cm diameter). The time to descend to the floor was measured. 
The test was recorded with a maximum duration of 60 s and repeated 
three to five times per animal.
Rotarod test
Mice were pretrained on a rotarod apparatus at 15 rpm for 300 or 
720 s to achieve stable performance. The test was conducted with a 
gradually accelerated speed from 4 to 40 rpm over a period of 300 s, 
and the time each mouse was able to stay on the rod was recorded. 
Each animal was tested three to five times.
Immunohistochemistry
Animals were deeply anesthetized with a Zoletil:Rompun mixture and 
were perfused with saline and 4% paraformaldehyde (PFA; BIOSESANG) 
for 15 to 20 min. Brains were quickly fixed with 4% PFA for 2 hours 
at 4°C, incubated with 30% sucrose (DAEJUNG) at 4°C for 48 hours, 
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and embedded with optimal cutting temperature (OCT) compound 
(Leica Biosystems), and cryosections (30-m thickness) were cut. 
Endogenous peroxidase activity was blocked by incubating the 
sections with 3% H2O2 (DAEJUNG) in methanol for 15 min. After 
washing in PBS, sections were incubated with blocking solution 
(1.5% normal goat serum in PBS; Vector Laboratories, S-1000) for 
30 min. Sections were incubated with rabbit polyclonal TH antibody 
(1:1000; Millipore, AB152) at 4°C for 24 hours, followed by biotinylated 
rabbit anti-rat immunoglobulin G (IgG; 1:200; Vector Laboratories, 
BA-1000) for 1 hour at room temperature; sections were subsequently 
treated with avidin-biotinylated peroxidase complex using an ABC 
Kit (Vector Laboratories, PK-6100) for 30 min at room temperature. 
The sections were then treated with 3,30-diaminobenzidine (DAB 
peroxidase substrate kit, Vector Laboratories) as a chromogen. 
Permanently mounted slides were observed and photographed 
using a microscope equipped with a digital imaging system (DS-
Ri2, Nikon). For fluorescence immunohistochemistry (IHC), rabbit 
polyclonal TH antibody (Millipore, AB152), rabbit polyclonal 
-synuclein filament (Abcam, ab209538), and anti-rabbit pSer129- 
-synuclein (GeneTex, GTX50222) antibodies were applied to 
sections with a 1:1000 dilution at 4°C for 24 hours. After rinsing 
with PBS, sections were incubated with anti-rabbit Alexa 488 
secondary antibody (Thermo Fisher Scientific, A-11034) or anti- 
chicken Alexa 647 secondary antibody (Thermo Fisher Scientific, 
A-21449) at 1:2000 dilution for 1 hour at room temperature. Sections 
were mounted with 4′,6-diamidino-2-phenylindole (DAPI) mounting 
medium (Vector Laboratories, H-1200) and were observed and 
photographed using a confocal microscope equipped with a digital 
imaging system (TCS SP8-gSTED, Leica). To count TH+ neurons in 
the substantia nigra, brain samples were dissected in three series. 
All three series were taken from levels −4.8 to −5.6 mm (from anterior 
to posterior) to bregma. Each section was cryo-sectioned with a 
thickness of 20 m. Cells with a certain area of the fluorescent signal 
(serially detected with above 25 pixels in the binary black-white 
version of image) were judged to be TH+ and were manually counted. 
We counted 150 to 350 cells (per section) for quantification.
Thioflavin S staining of -synuclein aggregates
After defatting in xylene for 5 min and subsequently hydrating 
through a series of ethyl alcohol solutions (100, 95, 80, and 70%, 
5 min in each), cryosections were stained with 1% Thioflavin S 
(in distilled water; Sigma-Aldrich) for 60 min. The sections were 
subsequently dehydrated through a series of ethyl alcohol solutions 
(70, 80, 95, 100, 100%, 5 min in each one) and then placed in xylene for 
5 min before being coverslipped with mounting media. Permanently 
mounted slides were observed and photographed using a microscope 
equipped with a digital imaging system (DS-Ri2, Nikon).
Determination of plasma DA levels
Blood samples were collected with EDTA tubes (BD Biosciences) 
after behavior tests. The collected samples were centrifuged for 
20 min at 13,000 rpm at 4°C within 30 min after sample collection 
and analyzed using an ELISA kit (Dopamine High-Sensitive ELISA, 
Eagle Bioscience Inc.) following the manufacturer’s protocol.
Western blot analysis and ELISA for -synuclein clearance 
in animal studies
To analyze -synuclein clearance in brain samples, the isolated 
brains were homogenized in PRO-PREP lysis buffer (iNtRON 
Biotechnology) containing a protease inhibitor (Thermo Fisher 
Scientific). The quantified cell lysates were separated by 10% SDS–
polyacrylamide gel electrophoresis (PAGE) and transferred to 
nitrocellulose membranes (Bio-Rad). Membranes were incubated 
with primary antibodies against -synuclein (1:1000; Santa Cruz 
Biotechnology, SC-12767), TH (1:2000; Millipore, AB152), pSer129- 
-synuclein (1:5000; Abcam, ab51253), and -actin (1:100,000; 
Sigma-Aldrich, A3854) followed by secondary antibodies. After 
visualization using SuperSignal West Dura (Thermo Fisher Scientific), 
immunoblots were quantified with ImageJ software. For ELISA, 
brain samples were collected after behavior tests. The collected 
samples were centrifuged for 20 min at 13,000 rpm at 4°C within 
30 min after sample collection and analyzed using a commercially 
available -synuclein ELISA kit (AnaSpec) following the manufacturer’s 
direction.
Statistical analysis
The in vitro tests that were quantified in all graphs were inde-
pendently performed with a minimum sample number of n = 3 per 
group for appropriate statistical analysis [t test or analysis of vari-
ance (ANOVA)] following data collection for all quantified data. 
We performed appropriate statistical analysis to demonstrate statis-
tical significance between designated groups as numerous published 
data were presented (42). In addition, to confirm the significant 
findings (e.g., suppression of pathological -synuclein), we cross-
checked our meaningful data via repeated experiments with differ-
ent toxins (e.g., sodium arsenite versus rotenone) at different time 
points using diverse analysis methods such as fluorescence imaging, 
Western blot, and fluorescence-activated cell sorting performed 
by several researchers. Statistical analyses were performed with 
GraphPad Prism or Excel software using Student’s t test or one-way 
ANOVA. One-way ANOVA was followed by Tukey’s or Bonferroni 
multiple comparisons test. P < 0.05 was considered statistically sig-
nificant. Data are represented as the means ± SD or means ± SEM 
as indicated.
Ethics statement
Animal handling and experimental procedures were approved and 
performed in accordance with the guidelines of the Institutional 
Review Board of the Cellivery R&D Institute, Cellivery Therapeutics 
Inc. Male C57BL/6 mice on arrival were housed in groups of five to 
six in standard cages. Male Sprague-Dawley rats (~230 g) were 
housed in groups of three in standard cages. Animals were maintained 
under controlled temperature (22° ± 2°C) on a 12-hour dark/12-hour 
light cycle with free access to food and water. Two to three animals 
were accommodated per cage following surgery to prevent bullying 
and facilitate feeding.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/18/eaba1193/DC1
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